228 related articles for article (PubMed ID: 31073278)
1. Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway.
Song YA; Ma T; Zhang XY; Cheng XS; Olajuyin AM; Sun ZF; Zhang XJ
Cancer Cell Int; 2019; 19():117. PubMed ID: 31073278
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets.
Wei N; Song Y; Zhang F; Sun Z; Zhang X
Front Oncol; 2020; 10():1424. PubMed ID: 32923394
[No Abstract] [Full Text] [Related]
3. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
4. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
Huang L; Hou M; Liu J; Li Y; Shen W; Zhou Q
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):771-781. PubMed ID: 36419390
[TBL] [Abstract][Full Text] [Related]
5. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Lee Y; Choi YR; Kim KY; Shin DH
Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
[TBL] [Abstract][Full Text] [Related]
7. Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.
Liu Y; Xiong ZC; Sun X; Sun L; Zhang SL; Ma JT; Han CB
Transl Cancer Res; 2019 Sep; 8(5):2151-2163. PubMed ID: 35116965
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
[TBL] [Abstract][Full Text] [Related]
9. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Wu DW; Chen TC; Huang HS; Lee H
Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
[TBL] [Abstract][Full Text] [Related]
10. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
11. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells.
Fei SJ; Zhang XC; Dong S; Cheng H; Zhang YF; Huang L; Zhou HY; Xie Z; Chen ZH; Wu YL
PLoS One; 2013; 8(7):e69104. PubMed ID: 23874880
[TBL] [Abstract][Full Text] [Related]
12. HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.
Tang X; Jiang J; Zhu J; He N; Tan J
Mol Genet Genomics; 2019 Feb; 294(1):85-93. PubMed ID: 30196354
[TBL] [Abstract][Full Text] [Related]
13. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
14. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
[TBL] [Abstract][Full Text] [Related]
15. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Chang TH; Tsai MF; Su KY; Wu SG; Huang CP; Yu SL; Yu YL; Lan CC; Yang CH; Lin SB; Wu CP; Shih JY; Yang PC
Am J Respir Crit Care Med; 2011 Apr; 183(8):1071-9. PubMed ID: 21037017
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1.
Zhu J; Tao L; Jin L
Mol Med Rep; 2019 Feb; 19(2):1331-1339. PubMed ID: 30535506
[TBL] [Abstract][Full Text] [Related]
17. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.
Wang B; Jiang H; Wang L; Chen X; Wu K; Zhang S; Ma S; Xia B
Oncol Lett; 2017 May; 13(5):3494-3500. PubMed ID: 28529576
[TBL] [Abstract][Full Text] [Related]
18. N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells.
Yamauchi M; Yoshino I; Yamaguchi R; Shimamura T; Nagasaki M; Imoto S; Niida A; Koizumi F; Kohno T; Yokota J; Miyano S; Gotoh N
Am J Cancer Res; 2011; 1(7):823-33. PubMed ID: 22016830
[TBL] [Abstract][Full Text] [Related]
19. Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.
Li G; Ma Y; Yu M; Li X; Chen X; Gao Y; Cheng P; Zhang G; Wang X
J Cancer; 2021; 12(17):5286-5295. PubMed ID: 34335945
[TBL] [Abstract][Full Text] [Related]
20. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]